Skip to content
OpenCapital
Get started

Dogwood Therapeutics DWTX Stockholders' Equity before Treasury Stock

Other financials

Income statement

See full
Operating income-$5.1M-14.6%
Net income-$5.0M+54.4%
EPS (diluted)-$0.15+98.2%

Balance sheet

See full
Cash & equivalents$13.2M-24.6%
Total debt$144.9K-24.2%
Total equity$80.6M+1,038%
Total assets$95.2M-1.8%

Cash flow

See full
Operating cash flow-$4.6M+2.0%

Valuation

See full
Market cap$54.14M-57.6%
Enterprise value$41.06M-64.7%

Returns & leverage

See full
Return on equity-64.6%-29.8pp
Debt / equity0×0.0×
Current ratio5.9×-1.6×

Where this comes from

Reported directly by Dogwood Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquityBeforeTreasuryStock.

The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dogwood Therapeutics's stockholders' equity before treasury stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dogwood Therapeutics's stockholders' equity before treasury stock?
Dogwood Therapeutics (DWTX) reported stockholders' equity before treasury stock of $80.92M in Q1 2026.
How has Dogwood Therapeutics's stockholders' equity before treasury stock changed year-over-year?
Dogwood Therapeutics's stockholders' equity before treasury stock increased by 995.6% year-over-year, from $7.39M to $80.92M.
What is the long-term trend for Dogwood Therapeutics's stockholders' equity before treasury stock?
Over 3 years (2022 to 2025), Dogwood Therapeutics's stockholders' equity before treasury stock has grown at a 117.3% compound annual growth rate (CAGR), from $7.33M to $75.2M.